- Home
- UDMY vs ELVN Comparison
UDMY vs ELVN Comparison
Compare UDMY & ELVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UDMY
- ELVN
- Stock Information
- Founded
- UDMY 2009
- ELVN 2016
- Country
- UDMY United States
- ELVN United States
- Employees
- UDMY N/A
- ELVN N/A
- Industry
- UDMY Other Consumer Services
- ELVN Biotechnology: Pharmaceutical Preparations
- Sector
- UDMY Real Estate
- ELVN Health Care
- Exchange
- UDMY Nasdaq
- ELVN Nasdaq
- Market Cap
- UDMY 904.2M
- ELVN 927.8M
- IPO Year
- UDMY 2021
- ELVN 2020
- Fundamental
- Price
- UDMY $7.32
- ELVN $17.77
- Analyst Decision
- UDMY Buy
- ELVN Strong Buy
- Analyst Count
- UDMY 11
- ELVN 4
- Target Price
- UDMY $9.90
- ELVN $37.25
- AVG Volume (30 Days)
- UDMY 866.7K
- ELVN 361.5K
- Earning Date
- UDMY 07-30-2025
- ELVN 05-14-2025
- Dividend Yield
- UDMY N/A
- ELVN N/A
- EPS Growth
- UDMY N/A
- ELVN N/A
- EPS
- UDMY N/A
- ELVN N/A
- Revenue
- UDMY $790,019,000.00
- ELVN N/A
- Revenue This Year
- UDMY $1.87
- ELVN N/A
- Revenue Next Year
- UDMY $4.15
- ELVN N/A
- P/E Ratio
- UDMY N/A
- ELVN N/A
- Revenue Growth
- UDMY 5.43
- ELVN N/A
- 52 Week Low
- UDMY $5.68
- ELVN $13.30
- 52 Week High
- UDMY $10.61
- ELVN $30.03
- Technical
- Relative Strength Index (RSI)
- UDMY 58.35
- ELVN 49.54
- Support Level
- UDMY $6.70
- ELVN $15.81
- Resistance Level
- UDMY $7.50
- ELVN $17.54
- Average True Range (ATR)
- UDMY 0.25
- ELVN 1.30
- MACD
- UDMY 0.07
- ELVN -0.04
- Stochastic Oscillator
- UDMY 77.50
- ELVN 38.06
About UDMY Udemy Inc.
Udemy Inc operates a marketplace platform at the center of a vibrant knowledge network. The company operates under two operating and reportable segments Consumer and Enterprise, out of which the Enterprise segment derives the maximum revenue. Geographically, the company derives maximum revenue from North America. The company leverages data, technology, and insights for effective learning experiences. It helps individuals and organizations to possess effective skill acquisition and development with flexibility.
About ELVN Enliven Therapeutics Inc.
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. Its product candidates include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.